MA27711A1 - Derives de pyrazolo [1,5-a] pyrimidine - Google Patents
Derives de pyrazolo [1,5-a] pyrimidineInfo
- Publication number
- MA27711A1 MA27711A1 MA28441A MA28441A MA27711A1 MA 27711 A1 MA27711 A1 MA 27711A1 MA 28441 A MA28441 A MA 28441A MA 28441 A MA28441 A MA 28441A MA 27711 A1 MA27711 A1 MA 27711A1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolo
- pyrimidine derivatives
- disorder
- drugs
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Les dérivés de pyrimidine de Pyrazolo [1, 5-a] représentés par la formule I et leurs sels pharmaceutiquement acceptables exposent une activité de kinase excellente. Les médicaments comprenant les composés comme des éléments actifs sont par conséquent attendus d'être utiles comme des agents thérapeutiques ou prophylactique pour le trouble initié par la protéine kinase dans laquelle il est impliqué, tel que la maladie inflammatoire, maladie auto-immune, trouble de destruction d'os, cancer et/ou croissance de tumeur.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0304665A GB0304665D0 (en) | 2003-02-28 | 2003-02-28 | Compounds |
US50069503P | 2003-09-08 | 2003-09-08 | |
GB0329446A GB0329446D0 (en) | 2003-12-19 | 2003-12-19 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27711A1 true MA27711A1 (fr) | 2006-01-02 |
Family
ID=32931047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28441A MA27711A1 (fr) | 2003-02-28 | 2005-08-12 | Derives de pyrazolo [1,5-a] pyrimidine |
Country Status (12)
Country | Link |
---|---|
US (1) | US7557110B2 (fr) |
EP (1) | EP1599482A4 (fr) |
JP (1) | JP4564485B2 (fr) |
KR (1) | KR20050115252A (fr) |
AU (1) | AU2004215481B2 (fr) |
BR (1) | BRPI0407834A (fr) |
CA (1) | CA2516824A1 (fr) |
CO (1) | CO5650257A2 (fr) |
MA (1) | MA27711A1 (fr) |
MX (1) | MXPA05008955A (fr) |
NO (1) | NO20053955L (fr) |
WO (1) | WO2004076458A1 (fr) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20070270408A1 (en) * | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
EP1666468A4 (fr) * | 2003-09-09 | 2007-03-21 | Ono Pharmaceutical Co | Antagonistes crf et composes heterobicycliques |
US20070060595A1 (en) * | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
DE10357565A1 (de) * | 2003-12-10 | 2005-07-07 | Bayer Cropscience Ag | Pyrazolopyrimidine |
DE102004008807A1 (de) * | 2004-02-20 | 2005-09-08 | Bayer Cropscience Ag | Pyrazolopyrimidine |
WO2006033796A1 (fr) * | 2004-09-17 | 2006-03-30 | Wyeth | Pyrazolo [1,5-a] pyrimidines substituees et leur procede de fabrication |
US8138342B2 (en) * | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
JP2008524330A (ja) * | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | ピラゾロ[1,5−A]ピリミジンアデノシンA2a受容体アンタゴニスト |
DE102005007534A1 (de) * | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
EP1864986A4 (fr) * | 2005-03-17 | 2009-09-16 | Teijin Pharma Ltd | Derive de la pyrazolopyrimidine ou sel acceptable d un point de vue pharmaceutique de celui-ci |
US7473694B2 (en) | 2005-03-17 | 2009-01-06 | Teijin Pharma Limited | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof |
US7417053B2 (en) | 2005-04-07 | 2008-08-26 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |
WO2007017678A1 (fr) * | 2005-08-09 | 2007-02-15 | Eirx Therapeutics Limited | Composes de pyrazolo[1,5-a] pyrimidine et leurs compositions pharmaceutiques |
EP1926734A1 (fr) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Composes de pyrazolopyridine et de pyrazolopyrimidine utilises comme modulateurs d'enzymes kinases |
CN101312977B (zh) * | 2005-09-22 | 2012-06-13 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作激酶调节剂的稠合杂环化合物 |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
EP1942900B1 (fr) * | 2005-10-06 | 2015-06-03 | Merck Sharp & Dohme Corp. | Utilisation de derives de pyrazolo [1,5-a] pyrimidine comme inhibiteurs de proteines kinases procedes d'inhibition de proteines kinases |
WO2007051810A2 (fr) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Utilisation pharmaceutique d'amides substitues |
KR20080069189A (ko) * | 2005-11-01 | 2008-07-25 | 트랜스테크 파르마, 인크. | 치환된 아미드의 약학적 사용 |
WO2007107550A1 (fr) * | 2006-03-21 | 2007-09-27 | High Point Pharmaceuticals, Llc | Dérivés d'adamantane pour le traitement du syndrome métabolique |
MX2008012482A (es) * | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
US8053447B2 (en) | 2006-04-07 | 2011-11-08 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
CA2657078A1 (fr) * | 2006-07-13 | 2008-01-17 | High Point Pharmaceuticals, Llc | Composes actifs de 11beta-hydroxysteroide deshydrogenase de type 1 |
EP1878721A1 (fr) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides en tant qu'inhibiteurs de la 11-beta-hydroxysteroid dehydrogenase type 1 |
EP1900739A1 (fr) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Dérivés de diazolodiazine comme inhibiteurs de kinases |
JP5274805B2 (ja) * | 2006-09-20 | 2013-08-28 | 三菱化学株式会社 | フッ素化芳香族化合物の製造方法 |
EP1918291A1 (fr) * | 2006-10-30 | 2008-05-07 | Novartis AG | Dérives de pyrazole fusionnes substitués de 3-aminocarbonyle comme modulateurs de protéine kinase |
ZA200904916B (en) * | 2007-02-23 | 2010-09-29 | High Point Pharmaceuticals Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
WO2008101885A1 (fr) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | Nouveaux composés |
US8334305B2 (en) * | 2007-02-23 | 2012-12-18 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase |
US20110003856A1 (en) * | 2007-02-23 | 2011-01-06 | Soren Ebdrup | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
JP2010520864A (ja) * | 2007-03-09 | 2010-06-17 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | ヒドロキシステロイドデヒドロゲナーゼインヒビターとしてのインドール−及びベンズイミダゾールアミド類 |
JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11ベータ−hsd1活性化合物 |
CA2683852A1 (fr) * | 2007-04-11 | 2008-10-23 | High Point Pharmaceuticals, Llc | Nouveaux composes |
CA2685036A1 (fr) * | 2007-04-24 | 2008-11-06 | High Point Pharmaceuticals, Llc | Utilisation pharmaceutique d'amides substitues |
AU2008280135B2 (en) | 2007-07-26 | 2012-02-23 | Novartis Ag | Organic compounds |
TW200917962A (en) | 2007-08-27 | 2009-05-01 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
EP2225247A1 (fr) * | 2007-11-28 | 2010-09-08 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de protéine kinase |
JP5394404B2 (ja) * | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
US8461163B2 (en) | 2008-03-31 | 2013-06-11 | Takeda Pharmaceutical Company Limited | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 |
US8518931B2 (en) * | 2008-04-07 | 2013-08-27 | Irm Llc | Compounds and compositions as kinase inhibitors |
US8729083B2 (en) | 2008-09-24 | 2014-05-20 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8853125B2 (en) | 2008-09-24 | 2014-10-07 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
JP2012532176A (ja) | 2009-07-06 | 2012-12-13 | ビーエーエスエフ ソシエタス・ヨーロピア | 無脊椎動物系害虫防除用ピリダジン化合物 |
BR112012000149B8 (pt) | 2009-07-06 | 2021-01-12 | Basf Se | compostos de piridazina, método para controlar pragas invertebradas e método para proteger material de propagação de planta e/ou as plantas |
US9125414B2 (en) | 2009-07-24 | 2015-09-08 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
PL2509602T3 (pl) * | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
CA2784807C (fr) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase raf de type ii |
JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013074986A1 (fr) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase c-jun-n-terminale (jnk) |
WO2013144532A1 (fr) * | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | Dérivés de pyrimidine 3-cyano-5-arylamino -7-cycloalkylaminopyrrolo [1, 5-a] et leurs utilisations comme agents antitumoraux |
WO2014063061A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine |
ES2842876T3 (es) | 2012-12-07 | 2021-07-15 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
JP2016512816A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
EP2970289A1 (fr) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Composés utiles en tant qu'inhibiteurs de la kinase atr |
ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
EP3805218A1 (fr) * | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
BR112016028273B1 (pt) | 2014-06-05 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | Composto de fórmula i-a, forma sólida de um composto de fórmula i-1 e seu processo de preparação |
DK3157566T3 (da) | 2014-06-17 | 2019-07-22 | Vertex Pharma | Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer |
WO2016105528A2 (fr) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
CA2978518C (fr) * | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibiteurs de kinases cycline-dependantes |
EP3307728A4 (fr) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
EP4019515A1 (fr) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
EP3355926A4 (fr) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr |
AU2017319500C1 (en) | 2016-08-31 | 2022-10-20 | Les Laboratoires Servier | Inhibitors of cellular metabolic processes |
JP7216705B2 (ja) * | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用方法 |
CN111542522B (zh) * | 2017-08-11 | 2021-10-15 | 苏州韬略生物科技有限公司 | 可用作激酶抑制剂的被取代的吡唑并嘧啶 |
GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
CN112638915B (zh) * | 2018-09-10 | 2023-04-07 | 伊莱利利公司 | 用于治疗银屑病和系统性红斑狼疮的吡唑并[1,5-a]嘧啶-3-甲酰胺衍生物 |
WO2020081508A1 (fr) * | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Inhibiteurs de tyk2 et leurs utilisations |
AR117177A1 (es) * | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
CN113677347A (zh) * | 2019-02-07 | 2021-11-19 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
EA202192625A1 (ru) | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
IL292785A (en) | 2019-11-08 | 2022-07-01 | Ventyx Biosciences Inc | tyk2 pseudokinase ligands |
CA3167313A1 (fr) | 2020-02-12 | 2021-08-19 | Thomas John Bleisch | Derives de 7-(methylamino)pyrazolo [1,5-a]pyrimidine-3-carboxamide substitues |
AR121251A1 (es) | 2020-02-12 | 2022-05-04 | Lilly Co Eli | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida |
CN115925712A (zh) * | 2022-12-09 | 2023-04-07 | 南京友怡医药科技有限公司 | 一种靶向抗肿瘤药物化合物及其制备方法和应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69130683T2 (de) | 1991-04-22 | 1999-05-06 | Otsuka Pharma Co Ltd | PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL |
EP0628559B1 (fr) * | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Composés de pyrimidine et leur application comme agents pharmaceutiques |
US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US7662826B2 (en) | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
DE10223917A1 (de) | 2002-05-29 | 2003-12-11 | Bayer Cropscience Ag | Pyrazolopyrimidine |
KR20050033659A (ko) * | 2002-09-04 | 2005-04-12 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로[1,5-a]피리미딘 화합물 |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
KR20050057139A (ko) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
MXPA05002571A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
MXPA05002573A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
WO2004022562A1 (fr) * | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-arykl-imidazo[1,2-a]pyrazin-8-ylamines, procede de preparation et procede d'utilisation correspondants |
-
2004
- 2004-03-01 EP EP04716064A patent/EP1599482A4/fr not_active Withdrawn
- 2004-03-01 KR KR1020057015871A patent/KR20050115252A/ko not_active Application Discontinuation
- 2004-03-01 JP JP2006502687A patent/JP4564485B2/ja not_active Expired - Fee Related
- 2004-03-01 CA CA002516824A patent/CA2516824A1/fr not_active Abandoned
- 2004-03-01 BR BRPI0407834-9A patent/BRPI0407834A/pt not_active IP Right Cessation
- 2004-03-01 US US10/547,080 patent/US7557110B2/en not_active Expired - Fee Related
- 2004-03-01 AU AU2004215481A patent/AU2004215481B2/en not_active Expired - Fee Related
- 2004-03-01 MX MXPA05008955A patent/MXPA05008955A/es unknown
- 2004-03-01 WO PCT/JP2004/002522 patent/WO2004076458A1/fr active Application Filing
-
2005
- 2005-08-12 MA MA28441A patent/MA27711A1/fr unknown
- 2005-08-25 NO NO20053955A patent/NO20053955L/no not_active Application Discontinuation
- 2005-08-26 CO CO05085412A patent/CO5650257A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004215481A1 (en) | 2004-09-10 |
MXPA05008955A (es) | 2006-02-22 |
KR20050115252A (ko) | 2005-12-07 |
JP4564485B2 (ja) | 2010-10-20 |
EP1599482A4 (fr) | 2008-10-01 |
CA2516824A1 (fr) | 2004-09-10 |
NO20053955L (no) | 2005-09-22 |
US7557110B2 (en) | 2009-07-07 |
US20060189632A1 (en) | 2006-08-24 |
BRPI0407834A (pt) | 2006-02-14 |
CO5650257A2 (es) | 2006-06-30 |
EP1599482A1 (fr) | 2005-11-30 |
WO2004076458A1 (fr) | 2004-09-10 |
AU2004215481B2 (en) | 2010-11-11 |
NO20053955D0 (no) | 2005-08-25 |
JP2006519226A (ja) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27711A1 (fr) | Derives de pyrazolo [1,5-a] pyrimidine | |
MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
TNSN05250A1 (fr) | Pyrimidinones substituees | |
MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
RU2324684C2 (ru) | Пиримидиновые производные | |
ES2539518T3 (es) | Inhibidores de proteínas quinasas | |
TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
LU92154I2 (fr) | Axitinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable | |
EA200400283A1 (ru) | Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции | |
TNSN00239A1 (fr) | DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT | |
LU91407I2 (fr) | Sunitinib optionnellement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel l-malate (sutent) | |
ME00459B (me) | Aril fuzirana azapoliciklična jedinjenja | |
BR9812527A (pt) | Inibidores de benzenossulfonamida de pde-iv e seu uso terapêutico | |
MA27703A1 (fr) | Derives de diazepino-indole servant d'inhibiteurs de kinases | |
MY140872A (en) | 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders | |
MA26997A1 (fr) | Derives de 3-(4-amidopyrrole-2-ylmethylidene)-2-indolinone utilisables comme inhibiteurs de proteine-kinases | |
IL127965A0 (en) | Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same | |
MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
BR112021006033A2 (pt) | Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina | |
TNSN97044A1 (fr) | Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. | |
EA200301063A1 (ru) | Фармацевтические агенты для лечения ганв и микроаденом | |
ATE242246T1 (de) | (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel | |
HUP0301032A2 (hu) | Ciklin-dependens kinázok N-{5-[(5-alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren |